Associations of Dehydroepiandrosterone Sulfate With Cardiometabolic Risk Factors in Prepubertal Children

Mäntyselkä, Aino; Lindi, Virpi; Viitasalo, Anna; Eloranta, Aino-Maija; Ågren, Jyrki; Väisänen, Sari; Voutilainen, Raimo; Laitinen, Tomi; Lakka, Timo A.; Jääskeläinen, Jarmo

doi:10.1210/jc.2018-00184

Cited by 17 publications

(17 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the data are less uniform in females, with no association (He et al 2018 ) or a positive correlation observed in overweight-obese women (Bann et al 2015 ; De Simone et al 2001 ) and an inverse correlation observed in non-obese postmenopausal women (Casson et al 2010 ). However, DHEA-S appears to play a more significant role in women body composition, both in young females (De Simone et al 2001 ; Mäntyselkä et al 2018 ) and in adult ones (Barrett-Connor and Ferrara 1996 ; De Pergola et al 1994 ). The androgen receptor is expressed widely throughout the AT compartment, indicating that white AT adipocytes may be particularly sensitive to androgens (Newell-Fugate 2017 ).…”

Section: Discussionmentioning

confidence: 99%

Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies

2019

View full text Add to dashboard Cite

Introduction Obesity is a disorder characterized by a disproportionate increase in body weight in relation to height, mainly due to the accumulation of fat, and is considered a pandemic of the present century by many international health institutions. It is associated with several non-communicable chronic diseases, namely, metabolic syndrome, type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), and cancer. Metabolomics is a useful tool to evaluate changes in metabolites due to being overweight and obesity at the body fluid and cellular levels and to ascertain metabolic changes in metabolically unhealthy overweight and obese individuals (MUHO) compared to metabolically healthy individuals (MHO). Objectives We aimed to conduct a systematic review (SR) of human studies focused on identifying metabolomic signatures in obese individuals and obesity-related metabolic alterations, such as inflammation or oxidative stress. Methods We reviewed the literature to identify studies investigating the metabolomics profile of human obesity and that were published up to May 7th, 2019 in SCOPUS and PubMed through an SR. The quality of reporting was evaluated using an adapted of QUADOMICS. Results Thirty-three articles were included and classified according to four types of approaches. (i) studying the metabolic signature of obesity, (ii) studying the differential responses of obese and non-obese subjects to dietary challenges (iii) studies that used metabolomics to predict weight loss and aimed to assess the effects of weight loss interventions on the metabolomics profiles of overweight or obese human subjects (iv) articles that studied the effects of specific dietary patterns or dietary compounds on obesity-related metabolic alterations in humans. Conclusion The present SR provides state-of-the-art information about the use of metabolomics as an approach to understanding the dynamics of metabolic processes involved in human obesity and emphasizes metabolic signatures related to obesity phenotypes.

show abstract

Section: Discussionmentioning

confidence: 99%

Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies

2019

View full text Add to dashboard Cite

show abstract

“…There are data suggesting the negative effects of precocious/early adrenarche on future metabolic state, especially in women with a history of PA [ 29 , 30 ]. However, recent studies showed that there is no increased cardiometabolic risk in prepubertal children correlated with higher DHEAS [ 31 ]. In our AP group, the girls were predominant, during the follow-up more than half of them presented either impaired glucose tolerance or insulin resistance, only one had minor hypercholesterolaemia and hypertrigliceridaemia.…”

Section: Discussionmentioning

confidence: 99%

Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy

Lecka-Ambroziak

Wysocka‐Mincewicz

Marszałek-Dziuba

et al. 2020

Life

View full text Add to dashboard Cite

Puberty in children with Prader-Willi syndrome (PWS) is usually delayed and/or incomplete but in some patients premature/early adrenarche is observed. We assessed the premature adrenarche (PA) in PWS patients during the recombinant human growth hormone (rhGH) therapy and influence of PA on the course of central puberty (CP), rhGH efficacy and safety, and patients’ metabolic state. Forty-nine PWS patients were treated with rhGH, 11 presented with PA (group 1) and 14 had normal course of adrenarche (group 2). PA was observed in 22.5% of the PWS children treated with rhGH. The mean time between the rhGH start and the adrenarche, the rhGH dose, the growth velocity and the insulin-like growth factor 1 SD (IGF1 SD) during the treatment, as well as the time of CP, final height SD and BMI SD were similar in both groups. There were also no significant differences in the metabolic assessment—the oral glucose tolerance test (OGTT) and lipid profile results. PA may be a part of the clinical picture of PWS, apart from hypogonadotrophic hypogonadism and it seems to have no influence on CP in PWS patients. The rhGH efficacy and safety were comparable in the patients with PA and the normal course of adrenarche.

show abstract

“…Premature adrenarche has been associated with overweight/obesity and adverse glucose and lipid metabolism in both AGA- and SGA-born children [79-81]. Still, a recent study did not find an association between high DHEAS levels and adverse cardiometabolic risk factor levels, except higher BMI SDS, in healthy prepubertal primary school children [82]. Low birth weight was associated with higher circulating DHEAS [44, 83] and epinephrine [83] levels in childhood and birth weight had an inverse association with serum DHEAS levels all the way from SGA to LGA children [84, 85].…”

Section: Introductionmentioning

confidence: 99%

Birth Size as a Determinant of Cardiometabolic Risk Factors in Children

2020

Self Cite

View full text Add to dashboard Cite

The association between birth size and cardiometabolic disease risk may be U-shaped. Being born small for gestational age (SGA) has a definitive association with later cardiovascular risk, but the impact of being born large for gestational age (LGA) on cardiometabolic health is more controversial. In addition to birth size, early postnatal growth pattern and later weight gain affect cardiometabolic risk in adulthood. Most SGA-born children have catch-up and LGA-born children have catch-down growth during the first years of life. The extent of this early compensatory growth may contribute to the adverse health outcomes. Both SGA-and LGAborn children are at an increased risk for overweight and obesity. This may have a long-term impact on cardiometabolic health as overweight tends to track to adulthood. Other cardiometabolic risk factors, including alterations in glucose metabolism, dyslipidemia, hypertension, and lowgrade inflammation are associated with birth weight. Many of these risk factors are related to overweight or adverse fat distribution. Since later cardiometabolic risk is often mediated by early growth pattern and later overweight in SGA and LGA children, it is important to focus on staying normal weight throughout life. Hence, effective interventions to reduce cardiometabolic risk in LGA and SGA children should be developed.

show abstract

Associations of Dehydroepiandrosterone Sulfate With Cardiometabolic Risk Factors in Prepubertal Children

Cited by 17 publications

References 48 publications

Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies

Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies

Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy

Birth Size as a Determinant of Cardiometabolic Risk Factors in Children

Contact Info

Product

Resources

About